Showing 1781-1790 of 2526 results for "".
- Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Drugshttps://modernod.com/news/harrow-licenses-canadian-rights-to-apotex-for-five-branded-ophthalmic-drugs/2482117/Harrow and Canadian pharma company Apotex jointly announced an exclusive out-licensing agreement under which Apotex will market and distribute Verkazia and over-the-counter (OTC) Cationorm PLUS in the Canadian market, and concurrently, pursue market approval in Canada for Ve
- Johnson & Johnson Launches Tecnis PureSee Presbyopia-Correcting IOL in EMEAhttps://modernod.com/news/johnson-johnson-launches-tecnis-puresee-presbyopia-correcting-iol-in-emea/2482116/Johnson & Johnson MedTech announced that its Tecnis PureSee presbyopia-correcting IOL is now available in Europe, the Middle East, and Africa (EMEA). The Tecnis PureSee IOL features a proprietary, purely refractive design that delivers uninterrupted, high-quality, vision with high best-in-cat
- WashU Awarded up to $20M to Create Portable Device to Scan for Eye Diseaseshttps://modernod.com/news/washu-awarded-up-to-20m-to-create-portable-device-to-scan-for-eye-diseases/2482115/Chao Zhou, a professor of biomedical engineering in the McKelvey School of Engineering at Washington University in St. Louis, has been working to improve optical coherence tomography (OCT) systems that can conduct high-resolution imaging of the eyes. Now, with an up to $20 million contract from t
- New Penn Study Finds Promising Model for Restoring Cone Functionhttps://modernod.com/news/new-penn-study-finds-promising-model-for-restoring-cone-function/2482111/Vision scientists from the Division of Experimental Retinal Therapies at the University of Pennsylvania School of Veterinary Medicine used functional magnetic resonance imaging (fMRI) to assess brain responses to lights that stimulate only cone cells in dogs with naturally occurrin
- Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japanhttps://modernod.com/news/nicox-and-kowa-enter-into-agreement-for-ncx-470-development-and-commercialization-in-japan/2482106/Nicox SA announced the signature of an agreement granting Kowa exclusive Japanese rights to develop and commercialize NCX 470, Nicox’s nitric oxide (NO)-donating bimatoprost eye drop for the lowering of IOP in patients with glaucoma or ocular hypertension. Under the
- Toku Obtains CE and UKCA Marks for AI Cardiovascular Risk Assessments Through the Eyehttps://modernod.com/news/toku-obtains-ce-and-ukca-marks-for-ai-cardiovascular-risk-assessments-through-the-eye/2482096/Toku announced that it has obtained CE Mark in Europe and UKCA in the United Kingdom for its patented CLAiR technology, which provides a non-invasive evaluation for the risk of cardiovascular disease (CVD) at the point of care using retinal images captured during a routine eye exam
- Théa Acquires Rights to KIO-301 for the Treatment of Inherited Retinal Diseases in $301 Million Dealhttps://modernod.com/news/thea-acquires-rights-to-kio-301-for-the-treatment-of-inherited-retinal-diseases-in-301-million-deal/2482089/Kiora Pharmaceuticals announced that it has entered a strategic development and commercialization agreement with Théa Open Innovation (TOI), a sister company of Laboratoires Théa under with Kiora granted Théa exclusive worldwide development and commercialization rig
- Mega-Analysis Identifies Gene Variants Associated with Glaucoma in People of African Ancestryhttps://modernod.com/news/mega-analysis-identifies-gene-variants-associated-with-glaucoma-in-people-of-african-ancestry/2482072/A new analysis focusing specifically on people of African ancestry identified three gene variants that may be contributing to this population’s susceptibility to developing and being blinded by glaucoma, according to report from the Perelman School of Medicine at the University of Pennsylva
- Zeiss’ Visumax 800 With Smile Pro Software Approved by FDAhttps://modernod.com/news/zeiss-visumax-800-with-smile-pro-software-approved-by-fda/2482056/Zeiss Medical Technology announced that the FDA has approved the Visumax 800 With Smile Pro software for surgically treating nearsightedness, with or without astigmatism. This latest generation of femtosecond lasers from Zeiss enters the United States market as the technology is being broadly ado
- Eylea 8 mg Approved in EUhttps://modernod.com/news/eylea-8-mg-approved-in-eu/2482046/The European Commission has granted marketing authorization in the European Union (EU) for new Eylea 8 mg (aflibercept 8 mg, 114.3 mg/ml solution for injection) for the treatment of wet age-related macular degeneration (AMD) and visual impairment due to diabetic macular edema (DME).